Tokyo Tape
Sign in
← Medipal Holdings

Quarterly report · Q2

7459.TEDINET S100PLGZ
Period2022-04-01 → 2022-09-30
Filed2022-11-11
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 49
MetricValuePeriodScopeSource row
Revenue¥1.69T2022-04-01 → 2022-09-30Cons.Net sales
Revenue¥3.29T2021-04-01 → 2022-03-31Cons.Net sales (5-year summary)
Revenue¥1.64T2021-04-01 → 2021-09-30Cons.Net sales
Operating income¥25.5bn2022-04-01 → 2022-09-30Cons.Operating income
Operating income¥24.3bn2021-04-01 → 2021-09-30Cons.Operating income
Ordinary income¥33.3bn2022-04-01 → 2022-09-30Cons.Ordinary income
Ordinary income¥62.0bn2021-04-01 → 2022-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥33.6bn2021-04-01 → 2021-09-30Cons.Ordinary income
Profit before tax¥33.3bn2022-04-01 → 2022-09-30Cons.Income before income taxes
Profit before tax¥34.0bn2021-04-01 → 2021-09-30Cons.Income before income taxes
Net income (owners)¥17.3bn2022-04-01 → 2022-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥29.4bn2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥18.5bn2021-04-01 → 2021-09-30Cons.Profit loss attributable to owners of parent
Net income¥21.9bn2022-04-01 → 2022-09-30Cons.Profit loss
Net income¥23.8bn2021-04-01 → 2021-09-30Cons.Profit loss
Total assets¥1.74Tat 2022-09-30Cons.Assets
Total assets¥1.71Tat 2022-03-31Cons.Assets
Total assets¥1.72Tat 2021-09-30Cons.Total assets (5-year summary)
Total liabilities¥1.06Tat 2022-09-30Cons.Liabilities
Total liabilities¥1.06Tat 2022-03-31Cons.Liabilities
Net assets / equity¥674.7bnat 2022-09-30Cons.Net assets
Net assets / equity¥649.1bnat 2022-03-31Cons.Net assets
Net assets / equity¥657.2bnat 2021-09-30Cons.Net assets (5-year summary)
Cash and deposits¥221.2bnat 2022-09-30Cons.Cash and deposits
Cash and deposits¥243.2bnat 2022-03-31Cons.Cash and deposits
Cash & equivalents¥238.5bnat 2022-09-30Cons.Cash and cash equivalents
Cash & equivalents¥260.4bnat 2022-03-31Cons.Cash and cash equivalents
Cash & equivalents¥239.6bnat 2021-09-30Cons.Cash and cash equivalents
Cash & equivalents¥240.0bnat 2021-03-31dCons.Cash and cash equivalents
Operating cash flow−¥9.5bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in operating activities
Operating cash flow¥61.2bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥24.7bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥5.7bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥24.3bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥18.7bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in investment activities
Financing cash flow−¥6.7bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in financing activities
Financing cash flow−¥16.5bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥6.5bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in financing activities
EPS (basic)¥82.512022-04-01 → 2022-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥43.132022-07-01 → 2022-09-30dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥140.142021-04-01 → 2022-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥88.232021-04-01 → 2021-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥43.252021-07-01 → 2021-09-30dCons.Basic earnings loss per share (5-year summary)
EPS (diluted)¥77.562022-04-01 → 2022-09-30Cons.Diluted earnings per share (5-year summary)
EPS (diluted)¥131.412021-04-01 → 2022-03-31Cons.Diluted earnings per share (5-year summary)
EPS (diluted)¥82.792021-04-01 → 2021-09-30Cons.Diluted earnings per share (5-year summary)
Equity ratio31.8%at 2022-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio31.0%at 2022-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio31.2%at 2021-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 38
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-09-30−¥2.0bn
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-09-30−¥2.0bn
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-09-30¥191m
jpcrp040300-q2r_E02632-000Animal Health Products And Food Processing Raw Materials Wholesale Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥36.8bn
jpcrp040300-q2r_E02632-000Animal Health Products And Food Processing Raw Materials Wholesale Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥36.8bn
jpcrp040300-q2r_E02632-000Animal Health Products And Food Processing Raw Materials Wholesale Businessreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥1m
jpcrp040300-q2r_E02632-000Animal Health Products And Food Processing Raw Materials Wholesale Businessreportable segmentsegment profit2022-04-01 → 2022-09-30¥1.4bn
jpcrp040300-q2r_E02632-000Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥554.9bn
jpcrp040300-q2r_E02632-000Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥554.7bn
jpcrp040300-q2r_E02632-000Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥174m
jpcrp040300-q2r_E02632-000Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segmentsegment profit2022-04-01 → 2022-09-30¥12.0bn
jpcrp040300-q2r_E02632-000Prescription Pharmaceutical Wholesale Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥1.10T
jpcrp040300-q2r_E02632-000Prescription Pharmaceutical Wholesale Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥1.09T
jpcrp040300-q2r_E02632-000Prescription Pharmaceutical Wholesale Businessreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥1.8bn
jpcrp040300-q2r_E02632-000Prescription Pharmaceutical Wholesale Businessreportable segmentsegment profit2022-04-01 → 2022-09-30¥12.0bn
Total Of Reportable Segments And Otherssegment totalrevenue2022-04-01 → 2022-09-30¥1.69T
Total Of Reportable Segments And Otherssegment totalrevenue external2022-04-01 → 2022-09-30¥1.69T
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2022-04-01 → 2022-09-30¥2.0bn
Total Of Reportable Segments And Otherssegment totalsegment profit2022-04-01 → 2022-09-30¥25.4bn
Reconciling Itemsreconcilingrevenue2021-04-01 → 2021-09-30−¥1.9bn
Reconciling Itemsreconcilingrevenue intersegment2021-04-01 → 2021-09-30−¥1.9bn
Reconciling Itemsreconcilingsegment profit2021-04-01 → 2021-09-30¥304m
jpcrp040300-q2r_E02632-000Animal Health Products And Food Processing Raw Materials Wholesale Businessreportable segmentrevenue2021-04-01 → 2021-09-30¥35.9bn
jpcrp040300-q2r_E02632-000Animal Health Products And Food Processing Raw Materials Wholesale Businessreportable segmentrevenue external2021-04-01 → 2021-09-30¥35.9bn
jpcrp040300-q2r_E02632-000Animal Health Products And Food Processing Raw Materials Wholesale Businessreportable segmentrevenue intersegment2021-04-01 → 2021-09-30¥1m
jpcrp040300-q2r_E02632-000Animal Health Products And Food Processing Raw Materials Wholesale Businessreportable segmentsegment profit2021-04-01 → 2021-09-30¥1.3bn
jpcrp040300-q2r_E02632-000Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segmentrevenue2021-04-01 → 2021-09-30¥531.6bn
jpcrp040300-q2r_E02632-000Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segmentrevenue external2021-04-01 → 2021-09-30¥531.4bn
jpcrp040300-q2r_E02632-000Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segmentrevenue intersegment2021-04-01 → 2021-09-30¥175m
jpcrp040300-q2r_E02632-000Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segmentsegment profit2021-04-01 → 2021-09-30¥13.3bn
jpcrp040300-q2r_E02632-000Prescription Pharmaceutical Wholesale Businessreportable segmentrevenue2021-04-01 → 2021-09-30¥1.08T
jpcrp040300-q2r_E02632-000Prescription Pharmaceutical Wholesale Businessreportable segmentrevenue external2021-04-01 → 2021-09-30¥1.08T
jpcrp040300-q2r_E02632-000Prescription Pharmaceutical Wholesale Businessreportable segmentrevenue intersegment2021-04-01 → 2021-09-30¥1.7bn
jpcrp040300-q2r_E02632-000Prescription Pharmaceutical Wholesale Businessreportable segmentsegment profit2021-04-01 → 2021-09-30¥9.3bn
Total Of Reportable Segments And Otherssegment totalrevenue2021-04-01 → 2021-09-30¥1.65T
Total Of Reportable Segments And Otherssegment totalrevenue external2021-04-01 → 2021-09-30¥1.64T
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2021-04-01 → 2021-09-30¥1.9bn
Total Of Reportable Segments And Otherssegment totalsegment profit2021-04-01 → 2021-09-30¥24.0bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 510
ItemContextValueUnit
Depreciation sgaCurrentYTDDuration6064000000JPY
Other sgaPrior1YTDDuration19995000000JPY
Other sgaCurrentYTDDuration21851000000JPY
Selling general and administrative expensesPrior1YTDDuration84566000000JPY
Selling general and administrative expensesCurrentYTDDuration86006000000JPY
Operating incomePrior1YTDDuration24278000000JPY
Operating incomeCurrentYTDDuration25543000000JPY
Interest income noiPrior1YTDDuration89000000JPY
Interest income noiCurrentYTDDuration86000000JPY
Dividends income noiPrior1YTDDuration1301000000JPY
Dividends income noiCurrentYTDDuration1308000000JPY
Research fee income noiPrior1YTDDuration3940000000JPY
Research fee income noiCurrentYTDDuration4033000000JPY
Real estate rent noiPrior1YTDDuration655000000JPY
Real estate rent noiCurrentYTDDuration986000000JPY
Equity in earnings of affiliates noiPrior1YTDDuration3081000000JPY
Equity in earnings of affiliates noiCurrentYTDDuration1342000000JPY
Other noiPrior1YTDDuration532000000JPY
Other noiCurrentYTDDuration523000000JPY
Non operating incomePrior1YTDDuration9600000000JPY
Non operating incomeCurrentYTDDuration8281000000JPY
Interest expenses noePrior1YTDDuration9000000JPY
Interest expenses noeCurrentYTDDuration6000000JPY
Rent expenses on real estates noePrior1YTDDuration249000000JPY
Rent expenses on real estates noeCurrentYTDDuration508000000JPY
Other noePrior1YTDDuration62000000JPY
Other noeCurrentYTDDuration48000000JPY
Non operating expensesPrior1YTDDuration320000000JPY
Non operating expensesCurrentYTDDuration563000000JPY
Ordinary incomePrior1YTDDuration33558000000JPY
Ordinary incomeCurrentYTDDuration33261000000JPY
Gain on sales of noncurrent assets eiPrior1YTDDuration22000000JPY
Gain on sales of noncurrent assets eiCurrentYTDDuration16000000JPY
Gain on sales of investment securities eiPrior1YTDDuration47000000JPY
Gain on sales of investment securities eiCurrentYTDDuration3623000000JPY
Insurance income eiPrior1YTDDuration333000000JPY
Insurance income eiCurrentYTDDuration－JPY
Other eiPrior1YTDDuration95000000JPY
Other eiCurrentYTDDuration8000000JPY
Extraordinary incomePrior1YTDDuration499000000JPY
Extraordinary incomeCurrentYTDDuration3648000000JPY
Loss on sales and retirement of noncurrent assets elPrior1YTDDuration25000000JPY
Loss on sales and retirement of noncurrent assets elCurrentYTDDuration25000000JPY
Impairment loss elPrior1YTDDuration60000000JPY
Impairment loss elCurrentYTDDuration39000000JPY
Loss on valuation of investment securities elPrior1YTDDuration10000000JPY
Loss on valuation of investment securities elCurrentYTDDuration3316000000JPY
Other elPrior1YTDDuration2000000JPY
Other elCurrentYTDDuration185000000JPY
Extraordinary lossPrior1YTDDuration98000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2022-03-31pass rounding
balance sheet identityconsolidated 2022-09-30pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-03-31pass
statement vs summary · net assetsconsolidated 2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2021-04-01/2021-09-30pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-09-30pass
statement vs summary · revenueconsolidated 2021-04-01/2021-09-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-09-30pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsconsolidated 2022-09-30pass